Quant-iT™ microRNA 检测试剂盒
Use 96- and 384-well Microplates for Fluorescence-based Assays with Quant-iT assays for optimal results
Quant-iT™ microRNA 检测试剂盒
Invitrogen™

Quant-iT™ microRNA 检测试剂盒

使用 Quant-iT microRNA 测定试剂盒可轻松准确地定量测定 microRNA,该试剂盒是一种 microRNA (miRNA) 测定试剂盒,即使存在常见污染物(如盐、游离核苷酸了解更多信息
Have Questions?
货号数量
Q328821 kit
货号 Q32882
价格(CNY)
7,352.00
Each
添加至购物车
数量:
1 kit
价格(CNY)
7,352.00
Each
添加至购物车
使用 Quant-iT microRNA 测定试剂盒可轻松准确地定量测定 microRNA,该试剂盒是一种 microRNA (miRNA) 测定试剂盒,即使存在常见污染物(如盐、游离核苷酸、溶剂、去污剂和蛋白),也能检测 miRNA。相较于 rRNA 或较大的 mRNA (>1000 bp),该测定试剂盒对 microRNA 有高度选择性。

尽管该检测试剂并非专门对 miRNA 具有选择性,但我们可以根据提供的方案,甚至在存在 mRNA 的情况下,在低至 0.5 ng 的水平下重复定量测定纯样品中的 miRNA。

Quant-iT microRNA 测定试剂盒的特点包括:
• 灵敏检测微孔板孔中低至 0.5 ng 的 miRNA。
•5-500 ng/mL 的核心动态范围。
•在 50 ng/mL 至 100 µg/mL 的样品浓度范围内获得准确读数。

Quant-iT microRNA 测定试剂盒提供浓缩的测定试剂、稀释缓冲液和预稀释的 miRNA 标准品。只需按 1:200 的比例稀释试剂,将 200 µL 试剂上样至微孔板的孔中,加入 1-20 µL 样品,混合,然后读取荧光信号。该测定在室温下进行,信号可保持稳定约三小时。因为该测定试剂盒能够在 200 µL 的测定体积下承受 1–20 µL 的样品,所以在 50 ng/mL–100 µg/mL 的初始样品浓度内可获得准确结果。
仅供科研使用。不可用于诊断程序。
规格
检测microRNA 定量
激发/发射498/518
适用于(设备)荧光计、微孔板读数仪
反应次数1000(200 μL 测定体积)
产品线Quant-iT
定量范围1 至 100 ng
数量1 kit
检测方法荧光
Unit SizeEach

常见问题解答 (FAQ)

为什么我用Qubit Assay检测时会得到负的荧光值?

负的荧光值物理上是不可能的。它是由于软件自动扣除背景信号而造成的假象。这意味着你的荧光计检测到背景信号并将其扣除从而牺牲了真实数据。务必做一个仅有缓冲液的对照并评估信号的类型。你可能需要换用另外一块板。

Why am I getting negative fluorescence values with my Qubit Assays?

Negative fluorescence is a physical impossibility. It is an artifact from software autocorrecting for background signal. This means your reader is picking up and subtracting out background light at the cost of your data. Make sure to do a buffer-only control and assess the type of signal. You may need to switch to a different plate.

引用和文献 (5)

引用和文献
Abstract
MicroRNA detection based on duplex-specific nuclease-assisted target recycling and gold nanoparticle/graphene oxide nanocomposite-mediated electrocatalytic amplification.
Authors:Han Y, Qiu Z, Nawale GN, Varghese OP, Hilborn J, Tian B, Leifer K
Journal:Biosens Bioelectron
PubMed ID:30611105
DNA technology based bio-responsive nanomaterials have been widely studied as promising tools for biomedical applications. Gold nanoparticles (AuNPs) and graphene oxide (GO) sheets are representative zero- and two-dimensional nanomaterials that have long been combined with DNA technology for point-of-care diagnostics. Herein, a cascade amplification system based on duplex-specific nuclease (DSN)-assisted ... More
A universal fluorescence-based toolkit for real-time quantification of DNA and RNA nuclease activity.
Authors:Sheppard EC, Rogers S, Harmer NJ, Chahwan R
Journal:Sci Rep
PubMed ID:31222049
DNA and RNA nucleases play a critical role in a growing number of cellular processes ranging from DNA repair to immune surveillance. Nevertheless, many nucleases have unknown or poorly characterized activities. Elucidating nuclease substrate specificities and co-factors can support a more definitive understanding of cellular mechanisms in physiology and disease. ... More
Differences in the miRNA signatures of chronic musculoskeletal pain patients from neuropathic or nociceptive origins.
Authors:Dayer CF, Luthi F, Le Carré J, Vuistiner P, Terrier P, Benaim C, Giacobino JP, Léger B
Journal:PLoS One
PubMed ID:31276478
The quality of life for millions of people worldwide is affected by chronic pain. In addition to the effect of chronic pain on well-being, chronic pain has also been associated with poor health conditions and increased mortality. Due to its multifactorial origin, the classification of pain types remains challenging. MicroRNAs ... More
Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells.
Authors:Cristofolini T, Dalmina M, Sierra JA, Silva AH, Pasa AA, Pittella F, Creczynski-Pasa TB
Journal:Mater Sci Eng C Mater Biol Appl
PubMed ID:32228895
Breast cancer is a major cause of death among women worldwide. Resistance to conventional therapies has been observed in HER2-positive breast cancer patients, indicating the need for more effective treatments. Small interfering RNA (siRNA) therapy is an attractive strategy against HER2-positive tumors, but its success depends largely on the efficient ... More
Identification and Validation of MicroRNA Profiles in Fecal Samples for Detection of Colorectal Cancer.
Authors:Duran-Sanchon S, Moreno L, Augé JM, Serra-Burriel M, Cuatrecasas M, Moreira L, Martín A, Serradesanferm A, Pozo À, Costa R, Lacy A, Pellisé M, Lozano JJ, Gironella M, Castells A
Journal:Gastroenterology
PubMed ID:31622624
Screening for colorectal cancer (CRC) is effective in the population at average risk. The most extended strategy in organized programs involves the fecal immunochemical test, which is limited by low sensitivity for the detection of advanced adenomas (AAs). We aimed to identify microRNA (miRNA) signatures in fecal samples that identify ... More